Evaluating dry powder inhalers: From in vitro studies to mobile health technologies.

Arzu Ari, Bshayer Ramadan Alhamad

Respiratory medicine 2023 Aug-Sep

filter terms:

Dry powder inhalers (DPIs) are essential in treating patients with pulmonary diseases. Since DPIs were introduced in the 1960s, a remarkable improvement has been made in their technology, dose delivery, efficiency, reproducibility, stability, and performance based on safety and efficacy. While there are many DPIs on the market and several more under development, it is vital to evaluate the performance of DPIs for effective aerosol drug delivery to patients with respiratory disorders. Their performance evaluation includes the physicochemical properties of the drug powder formulation, metering system, device design, dose preparation, inhalation technique, and patient-device integration. The purpose of this paper is to review current literature evaluating DPIs through in vitro studies, computational fluid models, and in vivo/clinical studies. We will also explain how mobile health applications are used to monitor and evaluate patients' adherence to prescribed medications. Published by Elsevier Ltd.

Citation

Arzu Ari, Bshayer Ramadan Alhamad. Evaluating dry powder inhalers: From in vitro studies to mobile health technologies. Respiratory medicine. 2023 Aug-Sep;215:107281